C-4 Modified Sialosides Enhance Binding to Siglec-2 (CD22): Towards Potent Siglec Inhibitors for Immunoglycotherapy
Journal article published in 2013 by
Soerge Kelm,
Paul David Madge,
Tasneem Islam,
Ryan Bennett,
Hendrik Koliver-Brandl,
Mario Waespy,
Mark von Itzstein,
Thomas Erwin Haselhorst 
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
Two changes for the better: A novel class of sialic acid derivatives is prepared by modifying both the C-4 and C-9 positions of Neu5Aα2Me. This approach gives a lead compound that has sub-micromolar affinity for Siglec-2 and may provide a pathway for immunoglycotherapy strategies for autoimmune diseases and B cell derived non-Hodgkin's lymphoma.